• Liminatus Pharma regained Nasdaq compliance with the $1.00 minimum bid price rule, closing a delisting risk tied to sub-$1 trading.
• Nasdaq had flagged the stock on Jan. 15, 2026 for 30 straight business days below $1.00 under Global Market rules.
• The hearings panel moved the shares to the Nasdaq Capital Market effective Aug. 4, 2026, setting a Sept. 3 compliance deadline.
• A 1-for-50 reverse split took effect at the Aug. 20, 2026 close to support the bid price requirement.
• Nasdaq confirmed compliance based on 13 consecutive sessions above $1.00 from Aug. 21, 2026 to Sept. 9, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liminatus Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290900PRIMZONEFULLFEED9835208) on September 29, 2026, and is solely responsible for the information contained therein.